<DOC>
	<DOCNO>NCT00623727</DOCNO>
	<brief_summary>A study ass treatment new formulation recombinant factor VIII reconstitute liposome ( BAY79-4980 ) evaluate whether once-a-week treatment safe prevent bleeds subject severe haemophilia A .</brief_summary>
	<brief_title>BAY79-4980 Compared rFVIII-FS Previously Treated Patients With Severe Hemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Males age 12 70 year Subjects severe hemophilia A ( &lt; 1 % factor VIII [ FVIII ] : C ) Subjects equal great 150 exposure day ( EDs ) FVIII total Subjects ondemand treatment minimum 1 relevant bleed per month secondary prophylaxis treatment 3x/week schedule Subjects bleed event and/or treatment last 6 month prior study entry document subject medical record Subjects measurable inhibitor activity Subjects history FVIII inhibitor antibody formation Written inform consent subject parent / legal representative , &lt; 18 year Subjects receive primary prophylaxis Subjects prophylaxis document requirement &gt; 75 IU/kg/week Subjects bleed disease beside hemophilia A ( i.e. , von Willebrand disease ) Subjects abnormal renal function Subjects elevate hepatic transaminase Subjects treatment immunomodulatory agent within last 3 month prior study entry study Subjects know hypersensitivity active substance , mouse hamster protein , liposomes polyethyleneglycol ( PEG ) Subjects require premedication FVIII injection</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Hemophilia A</keyword>
	<keyword>FVIII disease</keyword>
	<keyword>rFVIII</keyword>
</DOC>